APL-话题@MedSci

#APL#

42篇内容 | 1128人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2202057, encodeId=aa1d220205ecb, content=<a href='/topic/show?id=c62a268958c' target=_blank style='color:#2F92EE;'>#依托泊苷#</a> <a href='/topic/show?id=52cb52309d9' target=_blank style='color:#2F92EE;'>#急性早幼粒细胞白血病#</a> <a href='/topic/show?id=6a8e264431' target=_blank style='color:#2F92EE;'>#APL#</a>, objectTitle=【BJH】全口服诱导方案治疗高危APL的回顾性研究：口服依托泊苷替代静脉化疗, objectType=article, longId=824532, objectId=1f3e8245326a, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/doctor-in-his-practice-with-a-digital-tablet-UWZKVBN.jpg, objectUrl=/article/show_article.do?id=1f3e8245326a, replyNumber=0, likeNumber=6, createdTime=2024-05-06, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=1f3e8245326a, moduleTitle=【BJH】全口服诱导方案治疗高危APL的回顾性研究：口服依托泊苷替代静脉化疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1f3e8245326a)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1509539, encodeId=cfec1509539f1, content=<a href='/topic/show?id=6a8e264431' target=_blank style='color:#2F92EE;'>#APL#</a>, objectTitle=2022 ASCO：基于查尔森合并症指数（CCI）预测急性早幼粒细胞白血病（APL）的早期死亡率和总生存期, objectType=article, longId=728460, objectId=e715e2846054, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e715e2846054, replyNumber=0, likeNumber=32, createdTime=2022-06-03, rootId=0, userName=风铃824, userId=c81c10095307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e715e2846054, moduleTitle=2022 ASCO：基于查尔森合并症指数（CCI）预测急性早幼粒细胞白血病（APL）的早期死亡率和总生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e715e2846054)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1509538, encodeId=d9a41509538bb, content=<a href='/topic/show?id=6a8e264431' target=_blank style='color:#2F92EE;'>#APL#</a>, objectTitle=APLAR痛风治疗临床实践指南VS2019年中国指南，9大项目对比，一文总结！, objectType=article, longId=293526, objectId=b27d293526e8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b27d293526e8, replyNumber=0, likeNumber=48, createdTime=2022-01-08, rootId=0, userName=风铃824, userId=c81c10095307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b27d293526e8, moduleTitle=APLAR痛风治疗临床实践指南VS2019年中国指南，9大项目对比，一文总结！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b27d293526e8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1509537, encodeId=b49b150953e48, content=<a href='/topic/show?id=6a8e264431' target=_blank style='color:#2F92EE;'>#APL#</a>, objectTitle=BJH：首次使用抗 VWF 纳米抗体 caplacizumab 治疗妊娠期 iTTP, objectType=article, longId=292586, objectId=8c3b292586ad, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8c3b292586ad, replyNumber=0, likeNumber=29, createdTime=2021-12-24, rootId=0, userName=风铃824, userId=c81c10095307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8c3b292586ad, moduleTitle=BJH：首次使用抗 VWF 纳米抗体 caplacizumab 治疗妊娠期 iTTP, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8c3b292586ad)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1509536, encodeId=b2831509536ad, content=<a href='/topic/show?id=6a8e264431' target=_blank style='color:#2F92EE;'>#APL#</a>, objectTitle=JCO：砷联合全反式维甲酸可安全有效治疗中国APL儿科患者！, objectType=article, longId=212313, objectId=f11b2123131f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f11b2123131f, replyNumber=0, likeNumber=38, createdTime=2021-06-06, rootId=0, userName=风铃824, userId=c81c10095307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f11b2123131f, moduleTitle=JCO：砷联合全反式维甲酸可安全有效治疗中国APL儿科患者！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f11b2123131f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1509535, encodeId=ab2d1509535b2, content=<a href='/topic/show?id=6a8e264431' target=_blank style='color:#2F92EE;'>#APL#</a>, objectTitle=英国批准Aplidin（plitidepsin）治疗COVID-19的III期临床试验, objectType=article, longId=207295, objectId=aa7320e295db, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aa7320e295db, replyNumber=0, likeNumber=30, createdTime=2021-02-20, rootId=0, userName=风铃824, userId=c81c10095307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aa7320e295db, moduleTitle=英国批准Aplidin（plitidepsin）治疗COVID-19的III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aa7320e295db)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1509534, encodeId=6ca115095349f, content=<a href='/topic/show?id=6a8e264431' target=_blank style='color:#2F92EE;'>#APL#</a>, objectTitle=Blood：纳米单抗Caplacizumab实际应用于TTP患者的真实临床数据, objectType=article, longId=203497, objectId=c7a020349eb3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c7a020349eb3, replyNumber=0, likeNumber=31, createdTime=2020-11-19, rootId=0, userName=风铃824, userId=c81c10095307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c7a020349eb3, moduleTitle=Blood：纳米单抗Caplacizumab实际应用于TTP患者的真实临床数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c7a020349eb3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1509533, encodeId=c65d1509533a7, content=<a href='/topic/show?id=6a8e264431' target=_blank style='color:#2F92EE;'>#APL#</a>, objectTitle=全球**纳米抗体Caplacizumab继FDA、EMA之后，再次获得NICE批准治疗罕见病患者的凝血障碍, objectType=article, longId=203477, objectId=04852034e7dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=04852034e7dd, replyNumber=0, likeNumber=44, createdTime=2020-11-18, rootId=0, userName=风铃824, userId=c81c10095307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=04852034e7dd, moduleTitle=全球**纳米抗体Caplacizumab继FDA、EMA之后，再次获得NICE批准治疗罕见病患者的凝血障碍, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=04852034e7dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1509532, encodeId=4286150953235, content=<a href='/topic/show?id=6a8e264431' target=_blank style='color:#2F92EE;'>#APL#</a>, objectTitle=APL-106治疗急性骨髓性白血病：将启动III期桥接研究, objectType=article, longId=201356, objectId=ba0c201356f9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ba0c201356f9, replyNumber=0, likeNumber=0, createdTime=2020-09-30, rootId=0, userName=风铃824, userId=c81c10095307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ba0c201356f9, moduleTitle=APL-106治疗急性骨髓性白血病：将启动III期桥接研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ba0c201356f9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1509531, encodeId=5c27150953133, content=<a href='/topic/show?id=6a8e264431' target=_blank style='color:#2F92EE;'>#APL#</a>, objectTitle=Nature:粘连蛋白释放因子Wapl促进V基因重排的机制, objectType=article, longId=198125, objectId=892b1981258e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=892b1981258e, replyNumber=0, likeNumber=42, createdTime=2020-07-29, rootId=0, userName=风铃824, userId=c81c10095307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=892b1981258e, moduleTitle=Nature:粘连蛋白释放因子Wapl促进V基因重排的机制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=892b1981258e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1509530, encodeId=064815095302a, content=<a href='/topic/show?id=6a8e264431' target=_blank style='color:#2F92EE;'>#APL#</a>, objectTitle=2018 APLAR：类风湿性关节炎的16条治疗建议, objectType=article, longId=196374, objectId=c9fa1963e441, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c9fa1963e441, replyNumber=0, likeNumber=25, createdTime=2020-06-25, rootId=0, userName=风铃824, userId=c81c10095307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c9fa1963e441, moduleTitle=2018 APLAR：类风湿性关节炎的16条治疗建议, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c9fa1963e441)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1509529, encodeId=ade31509529a4, content=<a href='/topic/show?id=6a8e264431' target=_blank style='color:#2F92EE;'>#APL#</a>, objectTitle=生存分析就是Kaplan-Meier法这一种吗？, objectType=article, longId=192205, objectId=484f1922055a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=484f1922055a, replyNumber=0, likeNumber=30, createdTime=2020-04-15, rootId=0, userName=风铃824, userId=c81c10095307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=484f1922055a, moduleTitle=生存分析就是Kaplan-Meier法这一种吗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=484f1922055a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1509528, encodeId=aa5b150952890, content=<a href='/topic/show?id=6a8e264431' target=_blank style='color:#2F92EE;'>#APL#</a>, objectTitle=2020 APAGE/APLAR/APSDE/APSH/APSN/PoA联合建议：高血压、心血管、肾脏或胃肠道共病患者应用非甾体类抗炎药治疗, objectType=article, longId=186657, objectId=063918665efa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=063918665efa, replyNumber=0, likeNumber=25, createdTime=2020-01-24, rootId=0, userName=风铃824, userId=c81c10095307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=063918665efa, moduleTitle=2020 APAGE/APLAR/APSDE/APSH/APSN/PoA联合建议：高血压、心血管、肾脏或胃肠道共病患者应用非甾体类抗炎药治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=063918665efa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1509527, encodeId=a489150952ec5, content=<a href='/topic/show?id=6a8e264431' target=_blank style='color:#2F92EE;'>#APL#</a>, objectTitle=Blood：基因突变结合基因表达水平分析可提高APL患者预后的预测, objectType=article, longId=175450, objectId=114a1e54507b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=114a1e54507b, replyNumber=0, likeNumber=35, createdTime=2019-07-16, rootId=0, userName=风铃824, userId=c81c10095307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=114a1e54507b, moduleTitle=Blood：基因突变结合基因表达水平分析可提高APL患者预后的预测, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=114a1e54507b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1509526, encodeId=e59c15095265c, content=<a href='/topic/show?id=6a8e264431' target=_blank style='color:#2F92EE;'>#APL#</a>, objectTitle=IJLH：使用西门子ADVIA 2120i和“APL标准”可以帮助降低APL的早期死亡率, objectType=article, longId=167570, objectId=dced16e570c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dced16e570c1, replyNumber=0, likeNumber=42, createdTime=2019-06-04, rootId=0, userName=风铃824, userId=c81c10095307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dced16e570c1, moduleTitle=IJLH：使用西门子ADVIA 2120i和“APL标准”可以帮助降低APL的早期死亡率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dced16e570c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1509525, encodeId=518c15095257b, content=<a href='/topic/show?id=6a8e264431' target=_blank style='color:#2F92EE;'>#APL#</a>, objectTitle=2018 APLAR建议：中轴型脊柱关节炎的治疗, objectType=article, longId=162432, objectId=0d9416243262, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0d9416243262, replyNumber=0, likeNumber=20, createdTime=2019-03-17, rootId=0, userName=风铃824, userId=c81c10095307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0d9416243262, moduleTitle=2018 APLAR建议：中轴型脊柱关节炎的治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0d9416243262)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1509524, encodeId=0117150952484, content=<a href='/topic/show?id=6a8e264431' target=_blank style='color:#2F92EE;'>#APL#</a>, objectTitle=2018 APLAR建议：类风湿性关节炎的治疗（更新版）, objectType=article, longId=162268, objectId=19121622681d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=19121622681d, replyNumber=0, likeNumber=0, createdTime=2019-03-14, rootId=0, userName=风铃824, userId=c81c10095307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=19121622681d, moduleTitle=2018 APLAR建议：类风湿性关节炎的治疗（更新版）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=19121622681d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1509523, encodeId=f53d1509523d1, content=<a href='/topic/show?id=6a8e264431' target=_blank style='color:#2F92EE;'>#APL#</a>, objectTitle=INT J LAB HEMATOL：诊断使用ADVIA 2120i Siemens和APL标准可以帮助降低APL的早期死亡率？, objectType=article, longId=159070, objectId=f0c31590e0c4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f0c31590e0c4, replyNumber=0, likeNumber=29, createdTime=2019-01-29, rootId=0, userName=风铃824, userId=c81c10095307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f0c31590e0c4, moduleTitle=INT J LAB HEMATOL：诊断使用ADVIA 2120i Siemens和APL标准可以帮助降低APL的早期死亡率？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f0c31590e0c4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1509522, encodeId=c4fa150952238, content=<a href='/topic/show?id=6a8e264431' target=_blank style='color:#2F92EE;'>#APL#</a>, objectTitle=NEJM：Caplacizumab治疗获得性血栓性血小板减少性紫癜, objectType=article, longId=157831, objectId=e6d915e83128, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e6d915e83128, replyNumber=0, likeNumber=40, createdTime=2019-01-13, rootId=0, userName=风铃824, userId=c81c10095307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e6d915e83128, moduleTitle=NEJM：Caplacizumab治疗获得性血栓性血小板减少性紫癜, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e6d915e83128)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1509521, encodeId=72eb15095215b, content=<a href='/topic/show?id=6a8e264431' target=_blank style='color:#2F92EE;'>#APL#</a>, objectTitle=APL-2获得FDA的孤儿药物认定用于治疗C3肾小球病, objectType=article, longId=156443, objectId=a73015644339, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a73015644339, replyNumber=0, likeNumber=33, createdTime=2018-12-24, rootId=0, userName=风铃824, userId=c81c10095307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a73015644339, moduleTitle=APL-2获得FDA的孤儿药物认定用于治疗C3肾小球病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a73015644339)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

APL

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#依托泊苷# #急性早幼粒细胞白血病# #APL#

【BJH】全口服诱导方案治疗高危APL的回顾性研究：口服依托泊苷替代静脉化疗

2024-05-06发表于上海

风铃824 (审核中...)

前往app查看评论内容

#APL#

2022 ASCO：基于查尔森合并症指数（CCI）预测急性早幼粒细胞白血病（APL）的早期死亡率和总生存期

2022-06-03

风铃824 (审核中...)

前往app查看评论内容

#APL#

APLAR痛风治疗临床实践指南VS2019年中国指南，9大项目对比，一文总结！

2022-01-08

风铃824 (审核中...)

前往app查看评论内容

#APL#

BJH：首次使用抗 VWF 纳米抗体 caplacizumab 治疗妊娠期 iTTP

2021-12-24

风铃824 (审核中...)

前往app查看评论内容

#APL#

JCO：砷联合全反式维甲酸可安全有效治疗中国APL儿科患者！

2021-06-06

风铃824 (审核中...)

前往app查看评论内容

#APL#

英国批准Aplidin（plitidepsin）治疗COVID-19的III期临床试验

2021-02-20

风铃824 (审核中...)

前往app查看评论内容

#APL#

Blood：纳米单抗Caplacizumab实际应用于TTP患者的真实临床数据

2020-11-19

风铃824 (审核中...)

前往app查看评论内容

#APL#

全球**纳米抗体Caplacizumab继FDA、EMA之后，再次获得NICE批准治疗罕见病患者的凝血障碍

2020-11-18

风铃824 (审核中...)

前往app查看评论内容

#APL#

APL-106治疗急性骨髓性白血病：将启动III期桥接研究

2020-09-30

风铃824 (审核中...)

前往app查看评论内容

#APL#

Nature:粘连蛋白释放因子Wapl促进V基因重排的机制

2020-07-29

风铃824 (审核中...)

前往app查看评论内容

#APL#

2018 APLAR：类风湿性关节炎的16条治疗建议

2020-06-25

风铃824 (审核中...)

前往app查看评论内容

#APL#

生存分析就是Kaplan-Meier法这一种吗？

2020-04-15

风铃824 (审核中...)

前往app查看评论内容

#APL#

2020 APAGE/APLAR/APSDE/APSH/APSN/PoA联合建议：高血压、心血管、肾脏或胃肠道共病患者应用非甾体类抗炎药治疗

2020-01-24

风铃824 (审核中...)

前往app查看评论内容

#APL#

Blood：基因突变结合基因表达水平分析可提高APL患者预后的预测

2019-07-16

风铃824 (审核中...)

前往app查看评论内容

#APL#

IJLH：使用西门子ADVIA 2120i和“APL标准”可以帮助降低APL的早期死亡率

2019-06-04

风铃824 (审核中...)

前往app查看评论内容

#APL#

2018 APLAR建议：中轴型脊柱关节炎的治疗

2019-03-17

风铃824 (审核中...)

前往app查看评论内容

#APL#

2018 APLAR建议：类风湿性关节炎的治疗（更新版）

2019-03-14

风铃824 (审核中...)

前往app查看评论内容

#APL#

INT J LAB HEMATOL：诊断使用ADVIA 2120i Siemens和APL标准可以帮助降低APL的早期死亡率？

2019-01-29

风铃824 (审核中...)

前往app查看评论内容

#APL#

NEJM：Caplacizumab治疗获得性血栓性血小板减少性紫癜

2019-01-13

风铃824 (审核中...)

前往app查看评论内容

#APL#

APL-2获得FDA的孤儿药物认定用于治疗C3肾小球病

2018-12-24

科室
- - 订阅+
  - 更多科室
工具
服务